Quantcast

Fuse Science Inc. has appointed Dr. Doug Armstrong to an Independent Voting Director position on its board. R. Douglas Armstrong, Ph.D., has over 25 years of life science experience, with emphasis on early stage and emerging growth life science companies. Dr. Armstrong previously served as the Chief Executive Officer of TyraTech and Aastrom Biosciences (where he was also Chairman of the board), leading both through initial public offerings, and has been a member of the board for several other healthcare companies. He is currently a member of the senior management of Tekesta Capital Partners, a division of WestPark Capital, Inc., and is also a founding partner and president of Auxol Capital LLC, life science investment fund.

“Fuse Science offers a unique business proposition in the life sciences field and I am thrilled to be joining the team,” added Dr. Armstrong. “I believe my operational expertise in the biotech industry and, in particular, the public capital markets, can help guide the company through this important stage of its lifecycle and beyond.”

“I am extremely excited to welcome Dr. Armstrong to our Powered By Fuse™ team,” said Brian Tuffin, Fuse Science’s Chief Executive Officer. “There is no substitute for quality of talent and Dr. Armstrong brings a wealth of experience and capabilities that will have an immediate impact on the company’s progress.”

Dr. Armstrong also previously served as a staff scientist for The Burnham Institute (La Jolla Cancer Research Institute) and Assistant Professor, Department of Pharmacology and Cancer Research Institute at the University of California.  He holds a Ph.D. degree in Pharmacology from the Medical College of Virginia, and a BA degree in Chemistry from the University of Richmond.

Fuse Science is the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company has successfully developed and maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated “DROP” form that is simply applied under the tongue.  The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products.

Leave a Reply

Your email address will not be published. Required fields are marked *

*